Astria Therapeutics (ATXS)
(Real Time Quote from BATS)
$12.16 USD
-0.19 (-1.54%)
Updated Sep 20, 2024 09:40 AM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Astria Therapeutics, Inc. [ATXS]
Reports for Purchase
Showing records 1 - 20 ( 74 total )
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Highlights From the 2024 Wedbush Healthcare Conference
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Navenibart (STAR-0215) Prepping to Enter Phase 3 in 1Q25
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Continue To Look Ahead To Navenibart (STAR-0215) Data In 4Q25
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Keep On Moving Forward - STAR-0215 Remains On Track [1Q24 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; More Data on the 2H24 Horizon for ALPHA-STAR
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Right Answers in Hand; Now Need Time; Target Adjusted Down to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hitching Our Wagon To ALPHA-STAR; Increasing Target to $22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimism Builds For STAR-0215 in HAE; Positive Initial Phase 1b/2 Data Set Stage For Upcoming Pivotal Studies in 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As We Await a First Look at Phase 1b/2 ALPHA-STAR Data in HAE Patients, Where Does STAR-0215 Stand?
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; All Eyes on Imminent ALPHA-STAR Proof-of-Concept Data in HAE Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- HAE KOL Call Check: Revisiting The Therapeutic Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Wishing On A STAR(-0215): Revisiting The ALPHA-STAR Readout
Provider: Wedbush Securities Inc.
Analyst: CHICO L